Acute Pancreatitis Following VAD Chemotherapy Combination Consisting Of Vincristine, Doxorubicin, And Dexamethasone In A Newly Diagnosed Multiple Myeloma Patient: A Case Report.
S. Toprak, S. Ocal, B. Erismis, E. Yıldırım, R. Altun, S. Karakuş, I. Tek, P. Topçuoğlu
{"title":"Acute Pancreatitis Following VAD Chemotherapy Combination Consisting Of Vincristine, Doxorubicin, And Dexamethasone In A Newly Diagnosed Multiple Myeloma Patient: A Case Report.","authors":"S. Toprak, S. Ocal, B. Erismis, E. Yıldırım, R. Altun, S. Karakuş, I. Tek, P. Topçuoğlu","doi":"10.5580/2b68","DOIUrl":null,"url":null,"abstract":"Background/Aims: The frequency of drug-related gastrointestinal adverse effects, including pancreatitis, has increased with the development and use of chemotherapeutic agents. Methods: In our country, a combination of vincristine, doxorubicin, and dexamethasone is frequently used as the first line of therapy in newly diagnosed multiple myeloma. A case with acute pancreatitis that we believe to depend on this therapy is presented. Results: In this case, after treatment of the acute pancreatitis episode in a very dynamic process, a proteasome inhibitor and following high dose chemotherapy with melphalan were used for the primary disease. Currently the patient is under follow-up at remission. Conclusion: It is important to consider chemotherapeutic agents as a possible etiology for acute pancreatitis in patients presenting with gastrointestinal symptoms, even after a few exposures to the agent.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/2b68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Background/Aims: The frequency of drug-related gastrointestinal adverse effects, including pancreatitis, has increased with the development and use of chemotherapeutic agents. Methods: In our country, a combination of vincristine, doxorubicin, and dexamethasone is frequently used as the first line of therapy in newly diagnosed multiple myeloma. A case with acute pancreatitis that we believe to depend on this therapy is presented. Results: In this case, after treatment of the acute pancreatitis episode in a very dynamic process, a proteasome inhibitor and following high dose chemotherapy with melphalan were used for the primary disease. Currently the patient is under follow-up at remission. Conclusion: It is important to consider chemotherapeutic agents as a possible etiology for acute pancreatitis in patients presenting with gastrointestinal symptoms, even after a few exposures to the agent.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
